Battelle’s Post

🔬 In our latest blog, Lifebit unveils Drug Discovery 2.0 - a groundbreaking leap in drug development. Join CBDO Thorben Seeger as he highlights the pivotal role of data in accelerating pre-clinical drug research. Discover how innovative data-driven approaches are shaping the future of healthcare. 🌟 Read more: https://bit.ly/46JYZC0 Lifebit is committed to solving the most challenging problems in precision medicine, genomics and healthcare with a mission to create a world where access to biomedical data will never again be an obstacle to curing diseases. Want to find out more? Request a demo 👉 https://bit.ly/3S4EQ5k #DrugDiscovery #AIInHealthcare #InnovationInPharma #Lifebit

Three-dimensional human intestinal organoids (hIO) are widely used as a platform for biological and biomedical research. Read this exciting paper on how to establish and functionalizing human intestinal organoids for drug development, regenerative medicine, and biological investigations, using key "in-house" media formulations. #3D Cell Culture #MerckReagents #CuriousMinds

✳ We are thrilled to share our exclusive interview with the amazing Professor Don Ingber, founding director of the Wyss Institute at Harvard University and pioneer of the organs-on-chip #OoC technology. 🔵 Among the highlights of the interview, Prof. Ingber discussed the success of Emulate, Inc.'s Liver-chips in predicting drug-induced liver injury (#DILI), bone marrow chips and their potential to assess drug side effects and contribute to personalized medicine and the reasons that make #OoC technology a “revolutionary approach to better understand human diseases and assess drug toxicity.” 🔴 The researcher also emphasised the need for #robust methods and the necessity to #harmonize globally the quality of qualification of techniques and validation of criteria. He also mentioned the current obstacles to the acceptance of these new methods and social barriers, notably in regulatory toxicology. 🌟 The interview reflects both the positive and constructive vision of the researcher, and his enthusiasm regarding the evolution of biomedical research and the potential of OoC technology. Read the full interview EN➡️https://lnkd.in/eedsDxFF FR➡️https://lnkd.in/ey6A55p3 Subscribe to our quarterly review (in french) https://lnkd.in/e28sU-9j

We're heading to the 6th Targeted Protein Degradation Summit in Boston! 🖐️ Looking forward to the discussions around PROTACs, molecular glues, and next-gen tactics like AbTACs, and more. Got questions or thoughts on protein degradation? Let's connect and explore the future of protein degradation therapeutics together! https://bit.ly/3KOO1m3 #ProteinDegradation #PROTACs #TPDSummit

🔬 Exciting news from Bio-Techne We've developed a new application note on optimizing organoid culture. Discover how the activity and consistency of growth and differentiation factors influence experimental outcomes. 🧬💡 Whether you're studying disease mechanisms, drug screening, or personalized medicine, our insights can help propel your research forward. 🚀 Dive into the world of organoid culture with Bio-Techne and unlock new possibilities in biomedical research! 🌟 #Biotechne #Organoids #Research #Innovation

Liver-on-Chip technology mimics the microarchitecture and functions of the liver in a miniaturized format. Using human-derived cells and microfluidic systems, it allows for real-time monitoring of cellular responses, making it invaluable for clearance prediction, toxicity prediction, and disease modeling. It's a game-changer in pharmaceutical research, personalized medicine, and space medicine. Here, I discuss the 4 pivotal areas where liver-on-chips are expected to impact the drug discovery. 1. Predicting DILI: Repeated dosing (chronic DILI predictions) to immune system integration 2. Hepatic Clearance: Long-term transporters, metabolic enzymes, and albumin secretion activity to predicting clearance of metabolically stable compounds. 3. Multi-Organ Integration: PK profiles & bioavailability (Fa,Fg,Fh) predictions 4. Space Health & Liver-on-Chip: Microgravity to Personalized Medicine #OrganOnChips #LiverOnChips #SpaceMedicine #PersonalizedMedicine #MicrophysiologicalSystems #TissueChips

🧫 Curious about organoids? 🧬 Our app note delves deep into the world of these tiny yet mighty structures, mimicking real organs in the lab. Uncover the importance of growth factors and reagent consistency in cultivating these mini marvels. Embark on a journey through human organ development, disease modeling, and beyond! Check it out: #MiniOrgans #Organoids #LabScience

This month our CEO, Charlie Peppiatt, and Prolight Diagnostics' Head of Engineering, Paul Monaghan, discussed our progress on the development of Psyros, an innovative point-of-care (POC) system, with BioStock - Connecting Innovation and Capital magazine. Prolight Diagnostics has enlisted G&H | ITL as partner for this project, aiming to revolutionize near-patient diagnostics by enabling quick, sensitive, and accurate testing of biomarkers, initially focusing on troponin for myocardial infarction detection. In the article, Charlie Peppiatt provides insight to our project roadmap, outlining the journey from developing the compact optical module to creating the prototype instrument, with plans for clinical validation studies in 2025. “Psyros is ushering in a new era of precision medicine, and we take pride in helping Prolight bring this diagnostic technology to market. This partnership exemplifies our joint commitment to advancing healthcare through cutting-edge innovation.” - Charlie Peppiatt, CEO of G&H. From concept to completion, we are proud to partner with Prolight Diagnostics as their end-to-end manufacturing partner. Read the full article: https://hubs.ly/Q02thhsR0 🖱 #ABetterWorldWithPhotonics #GHPhotonics #LifeScience #LifeSciences #Diagnostics #PointOfCareTesting #PointOfCare #MedTech #BioTechology

🚩 New feature in Bioanalysis Zone: 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐦𝐮𝐥𝐭𝐢-𝐨𝐦𝐢𝐜𝐬 𝐞𝐫𝐚 𝐨𝐟 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 How will the landscape of #multiomics in drug development evolve over the next 3–5 years? How are mass spectrometry-based technologies, like those developed by Bruker, supporting this transformation? Read perspectives on these topics from Sapient's Mo Jain, MD PhD in this interview with the Bioanalysis Zone team: https://lnkd.in/gQXpK3b9

In #genetherapy, clinical tasks overlap and translational medicine digs deeper and takes longer. Rather than sequential development, many activities take place in parallel. Raul Lima, inSeption Group explains how that crunch on chemistry, manufacturing, and controls (CMC) personnel, as well as lab personnel, is difficult to navigate: https://lnkd.in/eS6sUKnS #CMO #IND #therapydevlopment